ClinicalTrials.gov
public full text
Public Domain
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
The purpose of this study is to determine if the addition of study drug (custirsen) can provide durable pain palliation for castrate resistant prostate cancer patients receiving docetaxel retreatment or cabazitaxel as a second line therapy.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Gastric Cancer#811166
- Prostate PMSABR Study#900563
- Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer#831770
- Manual Therapy on the Improvement of Functional Disability in Patients With Chronic Non Specific Low Back Pain#1059886
- Scheduling Nab-paclitaxel With Gemcitabine#912057
Record · ID 813565
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive